SAN FRANCISCO--(BUSINESS WIRE)-- Nuvelution Pharma, Inc., today announced that Kirk Ways M.D., Ph.D., has been named Chief Medical Officer effective immediately. Dr. Ways is a seasoned industry expert with over 30 years of experience in medical research and will support the Company’s objective in advancing late-stage clinical assets toward FDA approval. He will work alongside Barry Gertz, M.D., Ph.D., Chief Physician Scientist of Nuvelution Pharma.

“We are excited to have Dr. Ways join our leadership team as he is a highly valuable addition to the Company,” said Sandy Zweifach, President and CEO of Nuvelution Pharma. “His extensive experience in medicine discovery and development, clinical research and clinical medicine will be a tremendous asset to Nuvelution. Along with Dr. Gertz, Nuvelution has expanded its expertise in a broad spectrum of therapeutic areas to address the needs of potential collaboration partners. We look forward to working in close partnership with him.”

Dr. Ways has had extensive experience in pharmaceutical discovery and development. Prior to joining Nuvelution, Dr. Ways served as Development Head of Cardiovascular and Metabolism at Janssen Pharmaceuticals, Inc. Prior to joining Janssen, Dr. Ways served in leadership capacities at BioStratum Incorporated as Vice President and Chief Development Officer, Aventis as Senior Global Medical Leader and Project Team Leader and Lilly Research Laboratories as a Research Fellow with responsibilities for the preclinical and clinical development for agents treating the chronic complications of diabetes. Prior to joining the pharmaceutical industry, Dr. Ways served as Director of the Diabetes Center, Vice Chairman for the Department of Internal Medicine, Endocrinology Section Head and Professor of Medicine at East Carolina School of Medicine. An accomplished researcher, Dr. Ways has authored more than one hundred publications in the fields of diabetes and cancer.

Dr. Ways earned his M.D. with honors and a Ph.D. in Pharmacology from the University of North Carolina and graduated with a B.A. Magna Cum Laude from Bridgewater College.

“I am eager to be working with the accomplished team at Nuvelution and applying my expertise to further progressing the advancement of late-stage clinical assets in therapeutic areas of substantial unmet needs,” said Dr. Ways.

About Nuvelution Pharma

Nuvelution leverages its extensive knowledge, experience and relationships in the pharma and biotech industries to deploy capital in risk-sharing collaborations with companies where product development can be facilitated by both capital and human resources with the goal of making this model an essential tool for pharma and biotech companies to bring products to the market. For more information, please visit www.nvtpharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181025005090/en/